The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth
Authors:
- Valérian DormoyVDValérian Dormoy
- Sabrina DanilinSDSabrina Danilin
- Véronique LindnerVLVéronique Lindner
- Lionel ThomasLTLionel Thomas
- Sylvie RothhutSRSylvie Rothhut
- Catherine CoquardCCCatherine Coquard
- Jean-Jacques HelwigJHJean-Jacques Helwig
- Didier JacqminDJDidier Jacqmin
- Hervé LangHLHervé Lang
- Thierry MassfelderTMThierry Massfelder
Open Access
- 16 December 2009
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 8 (1) , 123
Abstract
Background: Human clear cell renal cell carcinoma (CRCC) remains resistant to therapies. Recent advances in Hypoxia Inducible Factors (HIF) molecular network led to targeted therapies, but unfortunately with only limited clinical significance. Elucidating the molecular processes involved in kidney tumorigenesis and resistance is central to the development of improved therapies, not only for kidney cancer but for many, if not all, cancer types. The oncogenic PI3K/Akt, NF-kB and MAPK pathways are critical for tumorigenesis. The sonic hedgehog (SHH) signaling pathway is crucial to normal development. Results: By quantitative RT-PCR and immunoblot, we report that the SHH signaling pathway is constitutively reactivated in tumors independently of the von Hippel-Lindau (VHL) tumor suppressor gene expression which is inactivated in the majority of CRCC. The inhibition of the SHH signaling pathway by the specific inhibitor cyclopamine abolished CRCC cell growth as assessed by cell counting, BrdU incorporation studies, fluorescence-activated cell sorting and β-galactosidase staining. Importantly, inhibition of the SHH pathway induced tumor regression in nude mice through inhibition of cell proliferation and neo-vascularization, and induction of apoptosis but not senescence assessed by in vivo studies, immunoblot and immunohistochemistry. Gli1, cyclin D1, Pax2, Lim1, VEGF, and TGF-β were exclusively expressed in tumors and were shown to be regulated by SHH, as evidenced by immunoblot after SHH inhibition. Using specific inhibitors and immunoblot, the activation of the oncogenic PI3K/Akt, NF-kB and MAPK pathways was decreased by SHH inhibition. Conclusions: These findings support targeting SHH for the treatment of CRCC and pave the way for innovative and additional investigations in a broad range of cancers.Keywords
This publication has 37 references indexed in Scilit:
- Hedgehog: functions and mechanismsGenes & Development, 2008
- Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivoJournal of Clinical Investigation, 2008
- Recent advances in targeted therapy for renal cell carcinomaCurrent Opinion in Urology, 2007
- Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in GlioblastomaStem Cells, 2007
- Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathwaysProceedings of the National Academy of Sciences, 2007
- The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal CarcinomaClinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and TumorigenicityCurrent Biology, 2007
- Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumoursNature, 2003
- Muscarinic Receptors Mediate Phospholipase C-dependent Activation of Protein Kinase B via Ca2+, ErbB3, and Phosphoinositide 3-Kinase in 1321N1 Astrocytoma CellsJournal of Biological Chemistry, 2002